Taysha Gene Therapies (TSHA) Leases (2022 - 2025)
Historic Leases for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $7.5 million.
- Taysha Gene Therapies' Leases fell 1400.09% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 1400.09%. This contributed to the annual value of $8.4 million for FY2024, which is 1253.39% down from last year.
- Latest data reveals that Taysha Gene Therapies reported Leases of $7.5 million as of Q3 2025, which was down 1400.09% from $7.8 million recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Leases ranged from a high of $10.9 million in Q4 2022 and a low of $7.5 million during Q3 2025
- Its 4-year average for Leases is $9.2 million, with a median of $9.1 million in 2024.
- Its Leases has fluctuated over the past 5 years, first crashed by 1191.64% in 2024, then crashed by 1400.09% in 2025.
- Quarter analysis of 4 years shows Taysha Gene Therapies' Leases stood at $10.9 million in 2022, then decreased by 12.44% to $9.6 million in 2023, then fell by 12.53% to $8.4 million in 2024, then dropped by 10.95% to $7.5 million in 2025.
- Its Leases stands at $7.5 million for Q3 2025, versus $7.8 million for Q2 2025 and $8.1 million for Q1 2025.